Pharma
Would lowering ANDA costs boost domestic generic drug production?
Mark Cuban recently told Healthcare Brew the costs “kill the economics” for drugmakers like his.
FDA Approvals
In-depth reporting on FDA approvals, from market shifts and clinical breakthroughs to the essential updates shaping the sector.
Pharma
What Trump’s psychedelics order means for healthcare
We may be getting closer to the first FDA-approved psychedelic treatment.
Pharma
Despite FDA crackdown, unapproved GLP-1s still threaten the industry
Legitimate compounders are threatened by false advertising of counterfeit GLP-1s, legal experts warn.
Pharma
Could relaxed regulations boost gene therapy for ultra-rare diseases?
Companies like Prime Medicine and Aurora Therapeutics are shooting their shot.
Pharma
What new advertising rules may mean for pharma companies
The Trump administration’s crackdown on direct-to-consumer pharma ads could make TV advertising “very expensive and very difficult,” one expert said.
Pharma
Sarepta to cut 36% of staff, add black-box warning to Elevidys
The layoffs come after two deaths of patients who had taken its most profitable product, Elevidys.
Pharma
Pharma tariffs are coming ‘very shortly.’ Here’s how they could impact healthcare
Companies are likely to see cost increases despite an initial exemption.
Navigate the healthcare industry
Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.
By subscribing, you accept our Terms & Privacy Policy.
